

Washington University School of Medicine

Digital Commons@Becker

2020-Current year OA Pubs

Open Access Publications

2022

Gain and loss of TASK3 channel function and its regulation by novel variation cause KCNK9 imprinting syndrome

Margot A. Cousin

Marwan Shinawi

et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4



Part of the [Medicine and Health Sciences Commons](#)

RESEARCH

Open Access



Gain and loss of TASK3 channel function and its regulation by novel variation cause *KCNK9* imprinting syndrome

Margot A. Cousin^{1,2†} , Emma L. Veale^{3†} , Nikita R. Dsouza⁴, Swarnendu Tripathi⁴, Robyn G. Holden³, Maria Arelin⁵, Geoffrey Beek⁶, Mir Reza Bekheirnia⁷, Jasmin Beygo⁸, Vikas Bhambhani⁶, Martin Bialer⁹, Stefania Bigoni¹⁰, Cyrus Boelman¹¹, Jenny Carmichael¹², Thomas Courtin¹³, Benjamin Cogne¹⁴, Ivana Dabaj^{15,16}, Diane Doummar¹⁷, Laura Fazilleau¹⁸, Alessandra Ferlini¹⁰ , Ralitzia H. Gavrilova^{2,19}, John M. Graham Jr²⁰, Tobias B. Haack^{21,22}, Jane Juusola²³, Sarina G. Kant^{24,25}, Saima Kayani²⁶, Boris Keren²⁷, Petra Ketteler^{8,28}, Chiara Klöckner²⁹, Tamara T. Koopmann²⁴, Teresa M. Kruisselbrink^{2,19}, Alma Kuechler⁸, Laëtitia Lambert^{30,31}, Xénia Latypova¹⁴, Robert Roger Lebel³², Magalie S. Leduc⁷, Emanuela Leonardi^{33,34}, Andrea M. Lewis⁷, Wendy Liew³⁵, Keren Machol^{7,36}, Samir Mardini³⁷, Kirsty McWalter²³, Cyril Mignot²⁷, Julie McLaughlin⁹, Alessandra Murgia^{33,34}, Vinodh Narayanan³⁸, Caroline Nava²⁷, Sonja Neuser²⁹, Mathilde Nizon¹⁴, Davide Ognibene¹⁰, Joohyun Park²², Konrad Platzer²⁹ , Céline Poirsier³⁹, Maximilian Radtke²⁹, Keri Ramsey³⁸, Cassandra K. Runke¹⁹, Maria J. Guillen Sacoto²³, Fernando Scaglia^{7,36,40}, Marwan Shinawi⁴¹, Stephanie Spranger⁴², Ee Shien Tan³⁵, John Taylor¹², Anne-Sophie Trentesaux¹⁸, Filippo Vairo^{2,19}, Rebecca Willaert^{23^}, Neda Zadeh^{43,44}, Raul Urrutia^{4,45}, Dusica Babovic-Vuksanovic^{2,19}, Michael T. Zimmermann^{4,46,47*} , Alistair Mathie^{3,48*}  and Eric W. Klee^{1,2,19*} 

Abstract

Background: Genomics enables individualized diagnosis and treatment, but large challenges remain to functionally interpret rare variants. To date, only one causative variant has been described for *KCNK9* imprinting syndrome (KIS). The genotypic and phenotypic spectrum of KIS has yet to be described and the precise mechanism of disease fully understood.

Methods: This study discovers mechanisms underlying *KCNK9* imprinting syndrome (KIS) by describing 15 novel *KCNK9* alterations from 47 KIS-affected individuals. We use clinical genetics and computer-assisted facial phenotyping

[†]Margot A. Cousin and Emma L. Veale contributed equally to this work.

[^]Rebecca Willaert is deceased.

*Correspondence: mtzimmermann@mcw.edu; a.a.mathie@kent.ac.uk; klee.eric@mayo.edu

¹⁹ Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA

⁴⁷ Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA

⁴⁸ School of Engineering, Arts, Science and Technology, University of Suffolk, Ipswich, UK

Full list of author information is available at the end of the article



to describe the phenotypic spectrum of KIS. We then interrogate the functional effects of the variants in the encoded TASK3 channel using sequence-based analysis, 3D molecular mechanic and dynamic protein modeling, and in vitro electrophysiological and functional methodologies.

Results: We describe the broader genetic and phenotypic variability for KIS in a cohort of individuals identifying an additional mutational hotspot at p.Arg131 and demonstrating the common features of this neurodevelopmental disorder to include motor and speech delay, intellectual disability, early feeding difficulties, muscular hypotonia, behavioral abnormalities, and dysmorphic features. The computational protein modeling and in vitro electrophysiological studies discover variability of the impact of *KCNK9* variants on TASK3 channel function identifying variants causing gain and others causing loss of conductance. The most consistent functional impact of *KCNK9* genetic variants, however, was altered channel regulation.

Conclusions: This study extends our understanding of KIS mechanisms demonstrating its complex etiology including gain and loss of channel function and consistent loss of channel regulation. These data are rapidly applicable to diagnostic strategies, as KIS is not identifiable from clinical features alone and thus should be molecularly diagnosed. Furthermore, our data suggests unique therapeutic strategies may be needed to address the specific functional consequences of *KCNK9* variation on channel function and regulation.

Keywords: *KCNK9* imprinting syndrome, TASK3 channel, Neurodevelopmental disorder, Electrophysiology, Computational protein modeling

Background

The field of clinical genomics is facing a challenge to the paradigm that single genetic variants define specific human diseases, or if a spectrum of genetic changes can produce the same disease, or even be therapeutically treated in the same way. Elucidating the precise mechanism of disease, especially for channelopathies where agonists or antagonists may be clinically available, may suggest specific pharmacotherapeutic interventional opportunities. *KCNK9* (MIM: 605874, NM_001282534.1) encodes the TASK3 (TWIK-related acid-sensitive K channel 3, K_{2p9.1}) protein, a member of the two-pore domain potassium (K2P) channel family [1, 2]. *KCNK9* is among a small number of paternally imprinted genes where only the maternal allele is expressed [3]. Recent mouse studies, however, have detected residual paternal expression in some brain regions [4]. *KCNK9* imprinting syndrome (KIS), also known as Birk-Barel syndrome (MIM: 612292), is a rare genetic disorder caused by a genetic alteration of the maternal copy of *KCNK9*, first reported with the causal variant, p.(Gly236Arg) [5], and two subsequent variants of uncertain significance (VUS) [6, 7]. KIS is characterized by pathophysiological symptoms, of variable severity, including dysmorphic features with elongated face, varying degrees of intellectual disability (ID), and congenital hypotonia [5, 8].

K2P channels participate in the stabilization of the resting membrane potential of excitable and non-excitable cells, regulating cell activity. *KCNK9*-encoded TASK3 channels are predominantly expressed in the central nervous system (CNS) where they contribute to background current in many neuronal populations [9, 10]. TASK3 knockout mice show a number of cognitive

impairments, and these channels are proposed to play a role in various pathologic conditions including epilepsy, pain and disorders of aldosterone secretion, respiratory stimulation, and sleep duration [9]. Highly regulated by physiological mediators, these channels are particularly sensitive to increased extracellular acidification, resulting in channel inhibition [1, 9]. These channels are also potently inhibited by activated G-protein-coupled receptors (GPCRs) that couple primarily through the G_{αq} protein family [11–13].

Because of the importance of this channel to human pathophysiology, several laboratories, including ours, have devoted efforts to mechanistically characterize its wild-type and variant-altered function. Electrophysiological studies of the p.Gly236Arg variant demonstrated reduced inwardly rectifying currents which is insensitive to extracellular pH- and GPCR-mediated regulation [14]. Transient expression of the p.Gly236Arg variant in cortical pyramidal neurons during development severely impaired migration, likely contributing to developmental disorder in KIS [15]. Mice lacking TASK3 (*Kcnk9*^{-/-}) have impaired memory [16], sleep perturbation [17], and resistance to despair behavior that has a link to depression [18]. Assuming a loss-of-function mechanism, treatment strategies have been proposed using channel-stimulatory drugs [8]. However, the precise mechanisms of KIS, and whether additional variants cause the same disorder has remained unknown.

The current study significantly advances the knowledge of this syndrome by comprehensively assessing 47 individuals with 19 unique *KCNK9* variants. We characterize 15 novel variants using

data modeling and cellular experiments to determine how each alteration changes channel function and interpret these data in the context of the clinical findings. We found that *KCNK9* variants can cause gain or loss of channel function, and both exhibit the pathognomonic characteristic of altered regulation. Importantly, gain-of-function alleles thus may not be amenable to channel-stimulatory drugs. Thus, this study provides new knowledge of significant biomedical relevance by advancing our current understanding of this syndrome and its pathobiological mechanisms while also demonstrating how computational and experimental methods can be integrated to solve disease mechanisms.

Methods

Participants

This study describes 47 affected individuals from 29 families. We describe 26 newly identified individuals from 22 families (families F1-17, F23, F24, F26, F27, and F29) accrued through professional communication as well as through GeneMatcher [19]. They were recruited from hospitals or clinics from the USA and other countries including the UK, Germany, Italy, France, The Netherlands, Canada, and Singapore. Clinical, phenotypic, and *KCNK9* genetic variant data were analyzed for each participant. All families providing new or updated data provided informed consent (F1-F19, F23, F24, F26-F27, and F29). Data for families F20-F22, F25 and F28 was abstracted from prior publications only. This study was approved by the Mayo Clinic Institutional Review Board, and local Ethics Committees. Family 9 was recruited to the Genomics England 100,000 Genomes Project. Previously published individuals with *KCNK9* variants are also described with summarized published data and/or updated unpublished clinical data [5–8]. Persons P18.1, P19.1, P20.1, and P21.1 in this study refer to the published Patients 1-4 from Graham et al. [8]. Family F22 refers to the Arab-Israeli kindred described by both Barel et al. and Graham et al. [5, 8]. Person P25.1 refers to the individual reported by Šedivá et al. [6], Family F27 was previously reported without detailed clinical information [20], and person P28.1 refers to BK-227-03 described by Guo et al. [7].

Variant identification

KCNK9 variants were identified through a variety of methods including gene panel testing or exome or genome sequencing through commercial clinical laboratories including Ambry Genetics (Aliso Viejo, CA), Baylor Genetics (Houston, TX), and GeneDx

(Gaithersburg, MD), academic clinical laboratories, or through research studies. Additional details are provided in the individual clinical histories in the Additional file 1: Supplementary Note.

Facial analysis

Face2Gene Research application (FDNA Inc., Boston, MA) using DeepGestalt technology (algorithm 19.1.9) [21] was used to evaluate the presence of a distinct facial pattern in individuals with *KCNK9* imprinting syndrome. Seventeen frontal photos of the face were obtained from unrelated affected individuals without glasses or black eye bars (individual: age at photo: P3.1: 9y, P6.1: 10y3m, P7.1: 9y, P8.1: 1y5m, P9.1: 12y-18y, P12.1: 2y2m; P13.1: 6y1m, P16.1: 17y, P18.1 (updated photo patient 1) [8]: 6y, P23.1: 1y3m, P24.1: 3m, P27.1: 6y1m, P29.1: 8y1m and published photos of patient 2 (P19.1: 11m), 3 (P20.1: 1y1m), and 4 (P21.1: 3y) from Graham et al. [8] and the individual (P25.1: 17y) described by Šedivá et al. [6] and compared to 17 control images matched for age, sex, and ethnicity provided by Face2Gene. To estimate the power of DeepGestalt in distinguishing affected individuals from controls, a cross validation scheme was used, including a series of binary comparisons between all groups. For these binary comparisons, the data was split randomly multiple times into training sets and test sets. Each such set contained half of the samples from the group, and this random process was repeated 10 times. The results of the comparisons are reported using the receiver operating characteristic (ROC) curve and area under the curve (AUC). The mean AUC=0.87 and AUC STD=0.07.

Molecular modeling

No experimentally solved structure currently exists for the protein encoded by *KCNK9*, TASK3. Therefore, we began molecular modeling from the canonical UniProt sequence, Q9NPC2-1, which corresponds to Ensembl transcript ENST00000303015 to search for existing experimental structures of homologous sequences using Clustal [22, 23] alignment to the Protein Data Bank (PDB) [24]. Using I-tasser [25], we generated homology-based models for the highest homology experimental structures - residues 1-271 from human *KCNK1* (PDB: 3ukm) [26] and *KCNK4* (PDB: 3um7) [27]. These models were evaluated for quality using online servers and standard metrics including PROCHECK [28], QMEAN [29], QMEANBrane [30], and VADAR [31]. We compared models to one another by calculations of their electrostatic potentials, volumes, and accessible surface areas using DaliLite [32] and APBS [33]. We summarized quality metrics at the residue level to evaluate if

differences in quality clustered in 3D. All structure metrics were within expectation for high-confidence membrane proteins. Regions that are embedded within the membrane have high quality scores, comparable to solvent-exposed loops on both intracellular and extracellular-facing sides, which have lower quality scores. We believe that these loops will be more flexible, and therefore, any individual static representation of them will be insufficient. Our use of replicates and comparison to wildtype (WT) will help control for errors in the initial placement of these loops and facilitate interpreting the effects of genomic variants.

After completion of the 3D molecular modeling work described above, an experimental structure for TASK1 (*KCNK3*) was released [34]. This protein is closer in sequence identity to TASK3 (62%) compared to the TWIK1 (*KCNK1*) and TRAAK (*KCNK4*) experimental structures used as templates in this study (27% and 28%, respectively) [26, 27]. In our model, all amino acids through Val243 are concordant with the TASK1 experimental structure. After Val243, our model was disordered and highly dynamic in simulations, concordant with the sequence not conforming to the C-terminal of TWIK1 or TRAAK. In TASK1-based models, Met249 faces into the membrane and we computed Met249Thr to be destabilizing, consistent in effect with our original analysis (see the “Results” section). Thus, our modeling was highly concordant with the TASK1-based model and we have interpreted variants using information from both.

An explicit molecular environment was generated using Visual Molecular Dynamics (VMD) [35] and CHARMM-GUI [36, 37]. An 80x80Å membrane bilayer patch of POPC was generated. The protein was oriented to the patch using sequence-based annotation of trans-membrane helices from UniProt and consensus annotations from MESSA [38]. Water was added to provide a 10 Å distance between TASK3 and environment boundaries. The environment was neutralized at 150 mM KCl by adding 75 K⁺ and 79 Cl⁻ ions. This initial explicit-environment system for WT TASK3 was used in further modeling, as described below.

Structure-based calculations

We scored genomic variants by 3D structure-based algorithms. First, we generated dimer models of each genomic variant using FoldX [39, 40] version 4 for computational mutagenesis and calculating folding stability changes upon mutation ($\Delta\Delta G_{\text{fold}}$). The explicit-environment WT TASK3 system was modified for each genomic variant using the FoldX-generated models. We also assessed the initial models using Frustratometer [41], to quantify how each genomic variant changes local

interactions, from a more integrated perspective that accounts for the many concurrent types of favorable and un-favorable interactions of the mutated residues.

Molecular dynamics simulations

We studied the dynamics of *KCNK9* genetic variants on TASK3, and how they affect ionic interactions, using molecular dynamics (MD) simulation as implemented in the NAMD [42] software and the CHARMM27 force field [43]. Each protein model was analyzed in triplicate, beginning with energy minimization for 10,000 steps. Next, harmonic constraints were added to protein non-hydrogen atoms and the system was heated to 300K over 300 ps using a Langevin thermostat. Protein constraints were gradually released over 1 ns. The entire system was simulated free of restraints for a further 32 ns. In total, we generated 110 ns of MD trajectory per variant. Across variants and replicates, we generated 2.3 μs of MD trajectory to study the effects of the variants in TASK3.

Molecular dynamics analysis

We calculated root mean-squared deviation (RMSD) and root mean-squared fluctuation (RMSF) values using C^α atoms after structurally aligning each trajectory to the initial WT conformation and ignoring the mobile C-terminus. We used principal component analysis (PCA) to summarize the dominant conformational changes across trajectories. PCs were calculated in Cartesian coordinates using C^α atoms. We calculated the radial distribution function (RDF) for ions using VMD. The RDF of K⁺ describes the normalized probability of observing K⁺ ions within concentric shells. Electrostatic surfaces were sampled over time by extracting periodic frames from each simulation and assessed them each using APBS [33, 44]. Analyses were carried out using a custom structural bioinformatics workflow and leveraging the bio3d R package [45]. Protein structures and trajectories were visualized using PyMOL [45, 46] and VMD [35]. We generated our time-dependent prediction of effect for each genomic variant using a manual synthesis across multiple structure- and dynamics-based metrics as well as manual inspection of the simulation trajectories.

Mammalian expression plasmids

Human TASK3 (GenbankTM AF212829) cDNA, was cloned into the pcDNA3.1⁺ vector (Invitrogen, Carlsbad, CA, USA), gifted by Helen Meadows (GlaxoSmithKline, Harlow, UK) or into the pAcGFP1-N1 fluorescent vector (Clontech-Takara Bio Europe). Plasmids encoding for the human M3 muscarinic acetylcholine receptor (GenbankTM AF498917) cDNA were obtained from the UMR cDNA Resource Center (Rollo, MO).

Mutagenesis

Each of the clinically identified *KCNK9* variants (Arg131Ser, Arg131His, Arg131Pro, Met132Arg, Phe135del, Met156Val, Met159Ile, Phe164Cys, Thr199Ala, Tyr205Cys, Gly236Arg, Ala237Asp, Met249Thr, Ala320Thr) were introduced by site-directed mutagenesis into human TASK3 cDNA using the QuikChange kit (Agilent, CA, USA) as previously described [14]. Oligonucleotide primers were synthesized by Eurofins MWG Operon, Ebersberg, Germany, and all constructs sequenced by DNA Sequencing & Services, MRC/PPU, University of Dundee, Scotland.

Cell culture

All experiments were performed using a modified human embryonic kidney 293 cell line, tsA201 (European Collection of Authenticated Cell Cultures; Sigma-Aldrich, UK), prepared and maintained as previously described [14]. Once cells reached 80% confluency, they were split and resuspended in media at a density of 7×10^4 and 0.5 mL transferred to a 4-well plate containing a poly-D-lysine-coated coverslip, ready for transfection the following day.

Transfection

Plasmids containing cDNA for either WT or a mutated TASK3 variant and a similar plasmid encoding the cDNA for green fluorescent protein (GFP) were co-transfected at a concentration of 0.5 μ g using a modified calcium-phosphate protocol, as previously described [14]. The cells were then incubated at 37 °C in 95% O₂ and 5% CO₂ for 4–6 h, before being washed with phosphate-buffered saline. The cells were used for experiments 18–24 h later. All variants were expressed as homodimeric channels (each α -subunit of the dimer expresses the incorporated mutation) for all experiments. For experiments measuring the effect of G-protein coupled receptors, M3 receptors were also included in the transfection at a concentration of 0.5 μ g.

Whole-cell patch-clamp electrophysiology

Currents were recorded from GFP-fluorescing tsA201 cells expressing the cDNA of interest using whole-cell patch-clamp in a voltage clamp configuration and a step-ramp voltage protocol as previously described [14] using an extracellular solution composed of 145 mM NaCl, 2.5 mM KCl, 3 mM MgCl₂, 1 mM CaCl₂ and 10 mM HEPES (pH adjusted to 7.4) and an intracellular pipette solution of 150 mM KCl, 3 mM MgCl₂, 5 mM EGTA, and 10 mM HEPES (pH adjusted to 7.4). All experiments were conducted at room temperature (20–25 °C), and currents were recorded using an Axopatch 1D patch clamp amplifier (Molecular Devices, Sunnyvale, CA), filtered at 2 kHz, digitized at 5 kHz. Extracellular control

solution and modulatory compounds were perfused at a rate of 4–5 mL min⁻¹.

Electrophysiology data analysis and statistics

Data analysis of whole-cell outward current and analysis software was as previously described in Cunningham et al. [47]. Current-voltage graphs were obtained from the voltage ramp (–120 mV to +20 mV). Data were expressed as the mean \pm 95% confidence intervals (CI), and *n* represents the number of individual cells recorded. Statistical analyses used were either a one-way ANOVA with a post-hoc Dunnett's multiple comparisons test or an unpaired/paired Student's *t*-test. Data was considered statistically different if *P* < 0.05 (*), *P* < 0.01 (**), *P* < 0.001 (***), and *P* < 0.0001 (****). Data from variants was compared with matched control data from WT TASK3 recorded either simultaneously or around the same calendar period and cell batch number.

Confocal microscopy

Colocalization studies were performed according to the detailed methods outlined in Cunningham et al. [47]. In brief, WT human TASK3 and human TASK3_Tyr205Cys cDNAs were subcloned into the pAcGFP1-N1 fluorescent vector (Clontech-Takara Bio Europe) to create a fusion construct with GFP and expressed in tsA201 cells using TurboFect transfection reagent (ThermoFisher, Loughborough, UK). Prior to fixing the cells, the plasma membranes of the cells were stained with CellMask Deep Red (CMR) (ThermoFisher, UK) and the nuclei with Hoechst 33528 (Sigma-Aldrich, UK). Coverslips of cells were mounted with Vectashield anti-fade mounting medium (Vector Laboratories, UK).

Confocal microscopy images were taken using a LSM 880 confocal microscope (Carl Zeiss, Oberkochen, Germany) and processed using Zen Black software (Carl Zeiss). Cells were excited with an argon laser at either 561, 488, or 405 nm for the CMR plasma membrane stain, pAcGFP fused channel and Hoechst 33528 stained nuclei, respectively.

Colocalization was determined using Zen Black software and Pearson's correlation coefficient (PCC) was used to represent the degree of co-localization.

Chemicals

Muscarine chloride, zinc chloride, dithiothreitol, 5-dithio-bis(2-nitrobenzoic acid), and methanethiosulfonates were all purchased from Sigma-Aldrich, UK. For high potassium (25 mM K) or acidic pH (pH 6.4) experimentation, the extracellular solution was adjusted accordingly. Muscarine chloride was added directly to extracellular solution at a concentration of 0.1 μ M prior to use.

Functional study correlation and variant pathogenicity classification

To appropriately weight the strength of functional evidence provided by computational modeling and in vitro electrophysiological studies, we generated a weighting scheme for each. For computational modeling, we primarily used four dynamic features as follows (see Additional file 2: Table S1): The “ Δ 3-HB bbn RMSD” is the change in protein backbone RMSD among the 3-helix bundles. Since the WT channel exhibits dynamics in simulations (median of 2.8 Å RMSD), we binned this metric into three levels based on how distorted the 3HBs were for each variant compared to WT: ≥ 0.3 Δ RMSD, within 0.3 Δ RMSD, and ≤ -0.3 Δ RMSD compared to WT simulations. The “SSR of Filter C $^{\alpha}$ RMSF” is the sum of squared residuals for the selectivity filter alpha-carbon RMSF, between WT and each variant. We binned this metric into three levels compared to WT: greater than 1.0, between 1.0 and 0.5, and less than 0.5. The selectivity filter depends not only on the backbone, but also on sidechain orientations. So, we quantified the “ Δ side chain heavy atom RMSD TIG (Thr-Ile-Gly) motifs” binned into greater than 0.5, within 0.5, and less than 0.0. Finally, we used “anti-chamber open/close by PCs” to indicate if a single PC feature indicated opening the antechamber, two PC features indicated opening, no change, a single feature of more closed antechamber, and two features of more closed antechamber (Additional file 3: Video S1). For the electrophysiological studies, we used a two-step approach applying more weight to current than the other measured channel attributes. We first weighted each assay result: current amplitude (0–3 corresponding to the level of statistical significance (0: not significant; 1: $0.001 < P < 0.01$; 2: $0.0001 < P < 0.001$; 3: $P < 0.0001$) and regulation by GPCR or by pH (0: not significant; 1: $P < 0.05$) and added weights for each variant (max weight=5). These were then rescaled to a 0–3 scale (0: sum weight=0; 1: sum weight=1; 2: sum weight=2–3; 3: sum weight >3). The only exception to this was the Tyr205Cys variant which had no measurable current but would have only received a sum weight of 3 since regulation by GPCR and pH could not be measured without any baseline current, but the damaging evidence was more significant than that weight alone.

Variants were classified according to the 2015 Guidelines by the American College of Medical Genetics and Genomics and Association for Molecular Pathology guidelines [48]. Per current ClinGen guidelines, PM2 was used as a supporting level of evidence [49]. Conservatively, PS2 was applied as a moderate level of evidence due to *KCNK9* being a paternally imprinted locus. PP3 was determined using CADD


[50], MutationTaster [51], PrimateAI [52], SIFT [53], and Polyphen2 [54] (dbNSFP version 4.1 [55]) applying supporting level of evidence when 3 or more tools predict a damaging impact (Additional file 2: Table S1). The weight for functional evidence (PS3) was applied using only the electrophysiological data by the rescaled weight (none=0; supporting=1; moderate=2; strong=3). Agreement between computational and in vitro impact of variants was assessed using Spearman correlation and linear regression models.

Results

Diverse genomic variation in *KCNK9*

This study describes 47 affected individuals with heterozygous *KCNK9* variants from 29 families. We summarize the originally described Arab-Israeli kindred of 15 affected individuals and six previously published singletons in addition to the 26 newly identified individuals from 22 families harboring 15 unique, novel *KCNK9* variants (Fig. 1A).

KCNK9 is paternally imprinted, allowing pathogenic variants to be present on the paternal allele without causing disease, and thus could be found in healthy populations. We observed that *KCNK9* is nearly intolerant to missense variation with a gnomAD (v2.1.1) [56] missense constraint Z -score=2.9 (observed/expected ratio=0.48; CI 0.41–0.56) where significant constraint is $Z > 3.09$. *KCNK9* is less constrained than other genes causing dominant neurodevelopmental disorders [57], however, and 9/19 variants (Additional file 2: Table S1) fall in constrained coding regions (CCR) > 95th percentile [58]. The identified *KCNK9* variants (Fig. 1A, B and Additional file 2: Table S1) are absent or extremely rare in the population and fall either within the transmembrane (TM) or the intracytoplasmic domains, without occurring in the extracellular regions of the protein, and most affect highly conserved residues (Fig. 1C). Six families carry the p.(Gly236Arg) variant affecting 20 individuals, a known alteration hotspot. Among the novel variation identified in our cohort, eight families with nine affected individuals carry missense alterations at Arg131, including five families with p.(Arg131His), and one each with p.(Arg131Cys), p.(Arg131Pro), and p.(Arg131Ser) in an affected sibling pair. Two siblings from an additional family have the neighboring residue modified by a p.(Met132Arg) variant. Additionally, two unrelated probands have a p.(Met159Ile) variant. The remaining variants identified were unique to each family. Congruent with *KCNK9* paternal imprinting, ten families demonstrated maternal inheritance and in 16 families the variant occurred de novo in the affected individual or the mother (Additional file 2: Table S1). Thus, we have identified



diverse genetic alteration of TASK3 channels associated with KIS that lacked mechanistic understanding and disease association, motivating the functional characterization of them.

Spectrum and variability of clinical phenotypes associated with *KCNK9* variation
By assessing the available clinical data, we describe the phenotypic spectrum and variability across our cohort

(Table 1). Detailed clinical histories are provided in the Additional file 1: Supplementary Note. Most individuals presented with neurodevelopmental delays, ID, hypotonia, behavioral abnormalities, and facial dysmorphism.

Neurologically, the majority of individuals were affected with mild to severe profound ID ($n=24$ families, 83%) and motor ($n=26$, 90%) and speech ($n=27$, 93%) delays with mild to profound muscular hypotonia ($n=25$, 86%) especially during infancy. This was often accompanied by myopathic changes on muscle biopsy and electromyography (EMG). Behavioral and cognitive abnormalities were common ($n=17$, 59%) and included attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and aggressive, impulsive, or violent behavior. For example, proband P6.1 displayed autistic features with stereotypies (Additional file 4: Video S2).


Afebrile seizures were reported in five families (17% of families, Additional file 5: Table S2). Five of 15 affected individuals from family F22 reportedly developed seizures, but without further detail [5, 8]. The four additional probands (P11.1, P12.1, P13.1, and P18.1) who reported afebrile seizures had seizure onset between 2 and 8 years of age. Seizures were well controlled with medication (single or combination therapy including lamotrigine, sodium valproate, clonazepam, or oxcarbazepine). In three of these individuals, febrile seizures and unconfirmed episodes concerning for seizures preceded afebrile seizures with onset as early as 1 month of age. Three additional individuals (P3.1, P4.1, and P29.1) reported febrile seizures only and P1.2 experienced episodes of suspected absence seizures that were not confirmed.

Dysmorphic features were reported in all individuals with data available (Table 1 and Fig. 1D). Analysis of facial photos (Fig. 1E) of 17 unrelated individuals with KIS compared to matched controls using unbiased facial recognition software [21] demonstrated a statistically significant difference in dysmorphic facial features across our cohort ($P=0.014$, $AUC=0.88 \pm 0.05$). The composite facial gestalt image demonstrates elongated face, arched eyebrows, downturned corners of the mouth, thin upper lip, tented upper lip, short philtrum, and bitemporal narrowing. Additional features including thick alveolar ridges, cleft or high palate, and tapered fingers were relatively common. Thus, these descriptions extend and refine the spectrum of signs and symptoms that characterize this syndrome.

TASK3 variants display altered molecular mechanics and dynamics properties

We used models of 3D TASK3 channels (Fig. 2A–C), leveraging experimental data from the gene family, in calculations of a variant's effect on the protein ($N=14$;

Table 2). Protein structural modeling in 3D enables calculations of specific biochemical and biophysical details. Such calculations provide information that is distinct from genomics algorithms [59] and enable us to evaluate variant impact on channel mechanics. Using the 3D models, we simulated TASK3 dynamics (Additional file 6: Fig. S1), which were consistent across technical replicates (not shown) and revealed mutation-specific mechanics (Fig. 2D–G; details in Additional file 1: Supplementary Note). Gly236Arg indeed occluded, placed positive charge within the channel antechamber (Fig. 2D) and distorted the selectivity filter (Additional file 6: Fig. S2A). The selectivity filter is characterized by a ring of hydrophobic and aromatic residues that form interactions between monomers and facilitate transport through the channel (Additional file 6: Fig. S2B). Simulations also showed rearrangements of the selectivity filter for Arg131His, while Met132Arg led to blockage of mutated channels and Phe135del distorted both regions, supporting an interpretation of reduced function (Additional file 2: Table S1). The remaining mutated channels, other than Phe164Cys and Ala237Asp, showed a more open channel interior in simulations (Table 2), which we interpreted as being more permissive to ion transport. Some variants simultaneously showed features that could associate with being less permissive, such as Arg131His which had a distorted selectivity filter, and Arg131Ser which had a narrower channel entrance. To better summarize aggregate effects across these protein dynamics changes, we quantified changes to K^+ distribution at key locations (Additional file 6: Fig. S3 and S4) and found severe depletion of K^+ nearby the selectivity filter for Gly236Arg (Fig. 3A). At the cytoplasmic face, Gly236Arg showed nearly no K^+ , Arg131His showed little, and Met159Ile comparatively more but still diminished compared to WT (Fig. 3B). Simulations even demonstrated the partial rescue of Gly236Arg by Ala237Thr co-mutation, previously shown experimentally [14] (Fig. 3C and Additional file 1: Supplementary Note), supporting the mechanistic value of the data. Interestingly, $[K^+]$ around the selectivity filter and $\Delta\Delta G_{\text{fold}}$ were significantly correlated ($\rho=0.50$), indicating a link between our structure- and dynamics-based calculations. Together, blinded to the electrophysiology data (below), simulations predicted loss of function for Gly236Arg, Phe135del, and Met132Arg, little change for Phe164Cys and Ala237Asp, likely gain of function, but with a mix of gain- and loss-associated features, for Met156Val, Arg131His, Arg131Ser, and gain of function for Arg131Pro, Met159Ile, Thr199Ala, and Met249Thr (Table 2). Thus, 3D structural and time-dynamic simulations enriched the information available from genomics, for explaining mutated TASK3 channel mechanics.



Electrophysiological studies reveal altered current by TASK3 variants

To evaluate the functional impact of *KCNK9* variants on TASK3 channel properties, we performed whole-cell patch clamp electrophysiology to record currents passing through 15 clinically identified *KCNK9* channel variants, transiently expressed in human tsA201 cells and characterize their properties, (Additional file 7: Table S3). The KIS variant, Gly236Arg, introduces a positively charged arginine in the TM4 region of the channel and gives significantly reduced ($P < 0.05$) and inwardly rectifying currents [14]. For 13 novel variants (Arg131Ser, Arg131Cys, Arg131His, Arg131Pro, Met132Arg, Phe135del, Met156Val, Met159Ile, p.Phe164Cys, Thr199Ala, p.Ala237Asp, Met249Thr, p.Ala320Thr), however, the opposite effect—outwardly rectifying pico-ampere (pA) currents—was observed, determined by ramp changes

in holding potential from -120 to $+20$ mV (Fig. 4A–C and Additional file 7: Table S3). Seven of these variants (Arg131Ser, Arg131Cys, Arg131His, Arg131Pro, Met159Ile, Thr199Ala, Met249Thr) had significantly increased outward currents ($P < 0.05$, unpaired *t*-test), while Met132Arg and Phe135del, located on the intracellular cytoplasmic loop between TM2 and TM3, had significantly ($P < 0.05$) reduced outward currents (Fig. 4A and Additional file 7: Table S3), compared to experimentally matched WT controls. Interestingly, the remaining four variants (Met156Val, Phe164Cys, Ala237Asp, Ala320Thr) were functionally indistinguishable from WT in this assay (Fig. 4A). Twelve variants had mean zero current potentials similar to WT ($P > 0.05$) and close to the equilibrium potential for K^+ under these recording conditions (Fig. 4A–C). The Phe135del variant was the

Table 2 *KCNK9* variants in this study assessed for TASK3 structure- and dynamics-based changes

| Protein variant | $\Delta\Delta G_{\text{fold}}$ | $\Delta\text{Four-body Pot.}$ | ΔSRLF | ΔPC^a | Transport events ^b | $\Delta\text{Elec surface}$ | Selectivity Filter [K ⁺] ^c | $\Delta[\text{K}^+]^c$ | Blinded prediction ^d |
|-----------------|--------------------------------|-------------------------------|---------------------|--|-------------------------------|-----------------------------|---|------------------------|---------------------------------|
| R131S | 1.36 ± 0.17 | -2.63 | 1.13 | PC2 (2.6 σ) | 8 | + | 0.39 | --- | Occluded-permissive |
| R131H | 1.05 ± 0.17 | -1.48 | 1.26 | n.s. | 4 | + | 1.42 | - | Mixed-permissive |
| R131P | 6.87 ± 0.65 | 4.34 | -0.71 | PC2 (-1.1 σ) PC3 (1.5 σ) | 10 | -- | 1.08 | -- | Mono-permissive |
| M132R | 2.74 ± 0.10 | 14.77 | -1.21 | PC3 (-1.1 σ) | 14 | n.s. | 2.30 | + | Mixed-permissive |
| F135del | NA | NA | NA | PC3 (-2.4 σ) | 9 | n.s. | 1.52 | - | Mixed-permissive |
| M156V | 2.54 ± 0.17 | -3.75 | 1.22 | n.s. | 6 | + | 0.62 | --- | Permissive |
| M159I | 8.01 ± 0.52 | -22.18 | 0.86 | n.s. | 8 | + | 1.93 | n.s. | Permissive |
| F164C | 3.48 ± 0.43 | -31.18 | -0.55 | PC1 (1.2 σ) | 8 | n.s. | 2.92 | ++ | Permissive |
| T199A | 0.92 ± 0.14 | 1.83 | 0.08 | PC2 (-2.7 σ) PC3 (2.3) | 12 | + | 1.93 | n.s. | Permissive |
| Y205C | 4.01 ± 0.63 | -5.57 | 2.94 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| G236R | -2.59 ± 0.54 | -3.41 | -0.46 | PC2 (-2.8 σ) PC3 (1.6 σ) | 0 | ++ | 0.25 | --- | Occluded |
| G236R & A237T | -2.40 ± 0.54 | 0.32 | NA | PC1 (-2.0 σ) PC3 (-2.4 σ) | 10 | ++ | 0.81 | -- | Occluded-attenuated |
| A237D | 5.36 ± 0.17 | 13.51 | -1.85 | PC2 (-1.3 σ) | 8 | n.s. | 1.37 | - | Permissive |
| A237T | 0.13 ± 0.07 | -0.60 | -0.76 | PC2 (-2.9 σ) | 4 | + | 1.80 | n.s. | Moderately permissive |
| M249T | 6.41 ± 0.83 | 5.09 | 0.59 | PC2 (-3.1 σ) PC3 (1.2 σ) | 1 | -- | 2.00 | n.s. | Permissive |

SRLF single residue level frustration, NA not applicable, n.d. not determined

^a PC alterations of at least 1 standard deviation (σ) away from WT are noted; others are labeled as not significant (n.s.); data used ignored the C-terminus (see Methods)

^b Compared to a WT value of 2 transport events

^c Defined based on the K⁺ radial distribution functions (Fig. S4 and S5) at 6.9 Å from residues 94 and 200. Comparisons are to the WT value of 1.8


^d Using only the computational simulation data, we predict if the variants will impair potassium transport or not

only variant that displayed a significant ($P < 0.05$) shift in reversal potential to become more depolarized, similar to that observed with Gly236Arg. Tyr205Cys occurs in the second pore (P2) region of the channel and was non-functional under our experimental conditions, with no measurable current and zero current potentials (Additional file 7: Table S3), indistinguishable from green fluorescent protein (GFP)-only transfected cells. Using fluorescently tagged channels in confocal microscopy of WT, Gly236Arg, and Tyr205Cys channels, we found that Tyr205Cys channels had similar TASK3 protein levels at the plasma membrane as WT channels (Additional file 6: Fig. S5), suggesting the Tyr205Cys variant is trafficked as efficiently to the plasma membrane as WT. Attempts to restore current through Tyr205Cys channels using cysteine-modifying agents (dithiothreitol (DTT), 5''-dithio-bis(2-nitrobenzoic acid) (DTNB or Ellman's), or methanethiosulfonates (MTS)) were unsuccessful (Additional file 6: Fig. S6). Thus, the novel variation studied was dissimilar to Gly236Arg and significantly different in current density from WT, supporting its role in defining KIS but with a distinct underlying mechanism.

Alterations in TASK3 regulation is a dysfunctional feature shared by KIS variants

Sensitivity to extracellular pH changes is a hallmark regulatory fingerprint for TASK3 channels. With a pKa of 6.7, TASK3 channels are inhibited by increased extracellular acidification from physiological pH [1, 60, 61]. Interestingly, Gly236Arg mutated channels demonstrate reduced sensitivity to extracellular acidification (Additional file 8: Table S4 and see Veale et al. [14]). By determining the pH sensitivity of the novel TASK3 variants, we find that ten of the 13 variants had decreased sensitivity to extracellular acidification from pH 7.4 to 6.4 (Fig. 4A, D and Additional file 8: Table S4) similar to Gly236Arg channels; we found no change in pH sensitivity with Met156Val, Met249Thr, or Ala320Thr. Tyr205Cys could not be measured due to a lack of measurable current at -40 mV. These data show that most variants are associated with a similar disruption of channel regulation by extracellular acidification as the Gly236Arg channels.

Notably, TASK3 channels are also regulated by activated GPCRs leading to inhibition, and Gly236Arg channels show complete loss of $G_{\alpha q}$ -mediated channel inhibition (Additional file 9: Table S5, and see Veale




et al., 2007, 2014) [13, 14]. Thus, we assayed the loss of G_{aq} -mediated channel inhibition in the presence of $0.1 \mu\text{M}$ muscarine and found that seven of the 13 channels (Arg131Ser, Arg131Cys, Arg131His, Arg131Pro, Phe135del, Met159Ile, Ala237Asp) exhibited significantly ($P < 0.05$) reduced G_{aq} -mediated inhibition (Fig. 4A, E and Additional file 9: Table S5) similar to Gly236Arg, whereas Ala320Thr exhibited increased sensitivity to G_{aq} -mediated inhibition. The five remaining variants, (Met132Arg, Met156Val, Phe164Cys, Thr199Ala, Met249Thr), retained a sensitivity to G_{aq} -mediated inhibition similar to WT controls (Fig. 4A). These studies show that activated GPCR regulation of TASK3 channels is altered by a majority of clinical variants, similar to Gly236Arg, and suggest channel regulation as a defining functional consequence of clinical *KCNK9* variation associated with KIS.

Integrated computational and experimental assessment of altered channel mechanisms

We assessed the congruency of the computational and experimental results and show the computational assessment, blinded to in vitro data, was concordant with in vitro data. We categorized the in vitro and computations evidence, each, into the following weights of impact (Additional file 2: Table S1; see methods for details): none (no change from WT; weight = 0),

supporting (differences are observed, but clinical significance is unclear; 1), moderate (function is likely impaired; 2), and strong (function is altered consistent with being disease causal; 3). All variants computationally predicted to occlude the channel were of strong impact, experimentally. Three of the four variants with computationally modeled features showing the channel being both more- and less-permissive were of strong impact (the fourth was of moderate impact), experimentally. Of the remaining six variants, four were of moderate impact and one each of supportive and strong impact, experimentally; among these six, computations were concordant with in vitro impact class but predicted a greater impact for Met156Val and Ala237Asp and a lesser impact for Met159Ile and Ala320Thr. Met156Val is unique among the in vitro tests for no measured impact on intrinsic function or regulation. A further three, Phe164Cys, Ala237Asp, and Ala320Thr, have minimal-to-no change in intrinsic protein function but do alter how it is regulated. Importantly, our computational models were not setup to test changes in channel regulation. Finally, Met159Ile has among the most damaging structure-based scores (Table 2). Thus, while we see fewer deformations of the Met159Ile channel in simulations, Met159Ile is predicted to alter the structure of TASK3. Therefore, the biochemical and mechanical link between our simulations and in vitro




data indicates their mutual value for interpreting the effects of genetic variants.

Then, we further datamined our simulations for which features associated best with experimental results. We found that alterations of position for the TIG motif that defines the selectivity filter and 3-Helix Bundle (3-HB) organization appear to be the most consistent structural features that associate with current amplitude changes (Additional file 2: Table S1). Four variants (Met132Arg, Phe135del, Gly236Arg, and Tyr205Cys) demonstrated decreased or no current amplitude experimentally. By computations, these four all showed greater distortion of 3-HB, compared to WT. Concurrently, Met132Arg and Phe135del had a more closed antechamber and Gly236Arg a more open antechamber. Thus, these four variants are predicted to be more conformationally unstable, leading to loss of amplitude. Six variants (Arg131Ser, Arg131His, Arg131Pro, Met159Ile, Thr199Ala, and Met249Thr) have increased amplitude by electrophysiology. All six except Arg131Ser had less distortion of 3-HB. Concurrently, Arg131Pro and Met249Thr have a more open antechamber, and Arg131His/Ser had a more closed antechamber. TIG motifs are significantly altered for all six except for Arg131Pro. Thus, these variants were overall more conformationally stable, but

TIG alteration indicated a loss of conformational control over ion movement. Three variants (Met156Val, Phe164Cys and Ala237Asp) demonstrated normal WT current amplitudes in electrophysiological assays. These three showed varied alteration of the 3-HBs and TIGs in simulations. A large 3-HB alteration was calculated for Ala237Asp, although no affect was seen on current amplitude, unlike the gain-of-function Ala237Thr synthetic variant [14, 62]. Deviation of the TIGs was minor for Phe164Cys and Met156Val but large for Ala237Asp. These three variants have mixed 3D features that support an overall neutral to modest increase in amplitude, concordant with our experiments. Thus, structural simulations and functional experiments provided inferences on how mutated TASK3 channels may become dysfunctional.

Correlation of functional properties of KIS variants and pathogenicity classifications

We next sought to classify the *KCNK9* variants using a 5-point pathogenicity scale from benign to pathogenic using all relevant and available data for each variant. DNA-based predictive algorithms were nearly unanimous in the variants being damaging, save p.(Met156Val) and p.(Ala320Thr) (Fig. 5A). Our in vitro



data was more nuanced and demonstrates that each variant can have unique features, but that channel regulation was most consistently disrupted (Fig. 5B). To gauge the strength of evidence supporting a damaging interpretation for the in vitro heterologous cell-based studies, and for the computational modeling studies, we used the four-point weights of impact calculated above (Additional file 2: Table S1; see methods for details). To classify the *KCNK9* variants in terms of pathogenicity, we used the current American College of Medical Genetics and Genomics and Association for Molecular Pathology guidelines [48] (Fig. 5C and Additional file 2: Table S1). Therefore, concordant with these guidelines, we considered only the in vitro cell-based studies as contributory for PS3 and applied the most weight to current amplitude (see methods for details). Using existing data, four of the 19 *KCNK9* variants

would be classified as pathogenic, seven as likely pathogenic, and eight remained VUS. The in vitro data we gathered in this study promoted three VUS to likely pathogenic and one likely pathogenic to pathogenic (Fig. 5C). Computations also demonstrated nuanced patterns, which we summarized above using distortion of the 3-HBs and TIGs (Fig. 5D). The variants had a very similar strength of evidence supporting a damaging impact on the protein from both experimental and computational approaches (Fig. 5E; rank correlation $\rho=0.72$, $P=0.0041$). Thus, the interpretation of our data in terms of these guidelines provides information of immediate application to clinical medicine, yet nuances from computational and in vitro experiments indicate that information with more detailed mechanistic value can improve the interpretation of KIS genetic variants.

Discussion

The current study makes significant contribution to the understanding of the field of channelopathies in general and to KIS, in particular, by characterizing a sizable cohort of individuals with novel genetic variants in *KCNK9* affected with this neurodevelopmental syndrome. In addition, we comprehensively characterize the functional impact of the variants using a multi-tiered approach. We report 26 previously unpublished individuals with 15 novel variants displaying phenotypic traits similar to those with the previously reported Gly236Arg variant associated with KIS. Moreover, we report the existence of two mutational hotspots in *KCNK9*, occurring at the previously reported Gly236 and the newly identified Arg131 codons. Computational protein modeling, molecular mechanic calculation, molecular dynamics simulations, and whole-cell patch-clamp electrophysiological techniques, when combined, strongly suggest that the large majority of these variants alter channel function and herein we classified them as pathogenic or likely pathogenic for KIS.

Fortunately, assembling this large mutational landscape for KIS allowed us to perform detailed clinical phenotyping of 47 affected individuals from 29 families with this syndrome (Table 1). The predominant features of this disorder include motor and speech delay, ID, early feeding difficulties, muscular hypotonia, behavioral abnormalities including hyperactivity and aggression, and dysmorphic features including an elongated face, permanent open mouth, microretrognathia, high arched eyebrows, and bitemporal narrowing. Less common features include seizures that can develop in childhood and were mostly controlled by medications, combined obstructive and central sleep apnea, and scoliosis. These features are consistent with the originally described p.(Gly236Arg) variant, but with a wider range of severity. Other syndromes that might be considered in the differential diagnosis include 22q deletion syndrome, Cohen syndrome, and Prader-Willi syndrome. The constellation of clinical features observed in KIS is not specific enough to make this disorder easily recognizable in the clinic, and it will therefore require a molecular diagnosis to confirm.

Unlike the original Gly236Arg mutant channels, which have reduced inwardly rectifying current [14], over 50% of the newly described variants had significantly increased outward currents. Notably, although the novel KIS variants had variable effects on channel current, they had a much more consistent impact on TASK3 regulation by extracellular pH and also by activated GPCRs. Taking into consideration general principles

of protein dynamics, genetic variants can shift the balance of motions and thereby alter protein function [63, 64]. Variants that occur at sites within the lower 3-HB (Arg131, Met132, Phe135, Met156, Met159, and Ala237) likely alter hydrophobic packing of the region giving an increased probability of K⁺ near the channel pore and more K⁺ transport events. This is in stark contrast to the decrease seen with Gly236Arg, suggesting distinct channel dysfunction by these novel variants. In particular, genetic variants at position 131 lead to different extents of distortion that pull the N-terminal helix inward while also pulling the 3-HB helices outward. These changes displace the C-terminus of the other monomer from its normal interaction, and it shifts inwards into the ion transport cavity. This shift is greatest for Arg131His with Arg131Pro and Arg131Ser having more variability between them. Thus, we believe distortion of the 3-HB configuration could provide a novel metric for tracking the disruption of the channel by genomic variants.

The Tyr205Cys variant occurring immediately after the conserved ion selectivity filter sequence (GFG) in the second pore region of the channel resulted in completely non-functional channels. This loss of function is most likely the consequence of replacing an amphipathic tyrosine with a hydrophobic cysteine residue in an aqueous environment. Aromatic residues such as tryptophan and tyrosine have been shown to be important in the pore region of KcsA (K channel of streptomyces A) channels in determining the final dimensions of the extracellular mouth of the pore [65].

Ideally, the rate of conductance from simulations would be directly relatable to experiments. While we observed multiple ion transport events, there were more ion transport events than WT in most mutated channel simulations, indicating that the length of simulations used may not be sufficient for direct computational measurement of conductance. Future studies will extend our initial work, such as determining the level of simulation details and time required to directly match experimental conductance measurements.

Overall, both the directionality and magnitude of changes seen through computational molecular structural assessment are largely concordant with the electrophysiological studies. This suggests that these assessments are not only useful in clarifying the underlying molecular causes of the measured electrophysiological changes but may also be used alone to provide evidence of pathogenicity. These data enabled the further clinical characterization of KIS and a better understanding of the mechanistic complexity underlying this rare genetic disorder. Currently, ACMGG/AMP guidelines for variant classification have criteria for computational

evidence (PP3) and for functional assays (PS3), but the rigor, breadth, and complexity of the computational studies described here fail to be adequately captured by PP3. When cell-based assays are not available for identified variants, the appropriate utilization of computational variant analysis for determining the pathogenicity of an individual variant will become critical and is feasible as herein demonstrated.

This study provides insight into the mechanistic complexity underlying this rare genetic disorder. It has demonstrated that *KCNK9* variants can cause a variety of effects on channel function ranging from upregulating to downregulating current to differing effects on regulation by G_{aq} and extracellular acidification. Yet, the dysregulation of TASK3, whether by an increase or decrease of channel properties, is sufficient to cause a single clinical disorder, KIS, not separable according to the specific functional impact. We may infer, then, that deviations from normal current density in either direction ultimately lead to the same overall physiological effect and clinical outcome. This has been shown in other genetic conditions involving several different potassium channels, including $K_{\text{v}}1.2$, $K_{\text{v}}2.1$, $K_{\text{v}}7.2$, and $K_{\text{ir}}1.2$ channels where, paradoxically, both loss and gain of function variants lead to hyperexcitability disorders such as epilepsy [66]. Further, the most consistent observation (for about 70% of the variants) is a loss of regulation. So perhaps, both during development and for functional responses in maturity, the most important observation is not the current size, per se, but the appropriate channel response to regulatory cues. In future work, further insight into the functional consequences of the differing effects of the *KCNK9* variants that we have described could be obtained from iPSC-derived neurons from patients harboring these variants. In addition to studying current through the mutated channels in the neurons themselves, this will allow us to measure the effects of the altered channel function on the excitability and firing patterns of these neurons and will provide a translational model for therapeutic evaluation.

The observed variable effects on channel function caused by the variants in *KCNK9* have further ramifications on potential therapy for KIS. It was previously hypothesized that channel-stimulatory drugs, such as a subset of the nonsteroidal anti-inflammatory fenamic acid class of drugs, may be useful in treating KIS as flufenamic acid had been shown to partially rescue the reduced current in Gly236Arg-mutated channels [14]. Graham et al. described the early results of treatment of two individuals with KIS with mefenamic acid suggesting positive effects [8]. The data presented in this study suggest that at a minimum these medications might only

be effective for individuals with a subset of variants causing reduced current, similar to that of Gly236Arg. These data may also suggest caution in treating an individual with normal or increased channel current as we might hypothesize exacerbated detrimental effects. However, it may also indicate that this approach may be challenging to appropriately dose for maximal efficacy or that without achieving proper channel regulation, little benefit may be achieved. An alternative strategy could be to increase expression of the normal paternal allele as demonstrated by Cooper et al. [4]. It is possible that paternal allele expression levels may be contributing to the phenotypic variability observed, and if determined, would support this as a possible treatment approach. It is interesting to hypothesize that clinical benefit may be achieved through treatment with medications such as valproic acid, a known histone deacetylase (HDAC) inhibitor, by promoting paternal allele expression. We observed two patients in our study with seizures treated with this medication showing good seizure control, but further work is needed to determine if other KIS-associated symptoms also show improvement.

Conclusions

In summary, KIS is a neurodevelopmental disorder caused by a spectrum of pathogenic variants on the maternal allele of the paternally imprinted *KCNK9* gene. Variants disrupt TASK3 channel function by causing gain or loss of current, or current regulation, demonstrating the complexity underlying the mechanism of disease, and likely requiring different methods of treatment. These findings further characterize the clinical features associated with this emerging disorder, demonstrate the utility of computational modeling for understanding variant impact on protein function, and bring caution and suggestions to potential treatment strategies for future studies.

Abbreviations

3-HB: 3-Helix bundle; ACMGG: American College of Medical Genetics and Genomics; ADHD: Attention deficit hyperactivity disorder; AMP: Association for Molecular Pathology; ASD: Autism spectrum disorder; CCR: Constrained coding regions; CI: Confidence intervals; CMR: CellMask Deep Red; CNS: Central nervous system; DTNB: 5''-Dithio-bis(2-nitrobenzoic acid); DTT: Dithiothreitol; EMG: Electromyography; GFP: Green fluorescent protein; GPCR: G-protein-coupled receptor; HDAC: Histone deacetylase; ID: Intellectual disability; K2P: Two-pore domain potassium channel family; KIS: *KCNK9* imprinting syndrome; MD: Molecular dynamics; MTS: Methanethiosulfonates; PCA: Principal component analysis; PCC: Pearson's correlation coefficient; PDB: Protein Data Bank; RDF: Radial distribution function; RMSD: Root mean-squared deviation; RMSF: Root mean-squared fluctuation; ROC: Receiver operating characteristic; AUC: Area under the curve; STD: Standard deviation; TASK3: TWIK-related acid-sensitive K channel 3, K2P9.1; TIG: Thr-Ile-Gly motif; TM: Transmembrane; VMD: Visual Molecular Dynamics; VUS: Variant of uncertain significance; WT: Wildtype.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13073-022-01064-4>.

Additional file 1: Supplementary Note. Clinical Histories. Written clinical histories including genetic testing for each novel family in this study. Molecular Modeling Reveals Mutation-Specific Effects on Channel Mechanics. Molecular Dynamics Simulations Show Changes in Potassium Ion Distribution.

Additional file 2: Table S1. *KCNK9* variants, impact summary, and ACMG classification.

Additional file 3: Video S1. Visualization of PC 1, 2, and 3 of the TASK3 dynamic modeling.

Additional file 4: Video S2. Video of proband P6.1 demonstrating autistic features with stereotypies.

Additional file 5: Table S2. Seizure and seizure-like episodes in affected individuals with at least one afebrile seizure.

Additional file 6: Figure S1. TASK3 conformational changes define PC motions and channel gating. **Figure S2.** Detailed view of the TASK3 selectivity filter and surrounding residues. **Figure S3.** Distributions of K⁺ ions for selected positions along the transport process, and across variants.

Figure S4. Genomic variants lead to changes in K⁺ concentration at the selectivity filter. **Figure S5.** Cellular localization of labelled TASK3 variants.

Figure S6. Comparison of whole cell current density for Tyr205Cys in the presence of various cysteine-modifying agents.

Additional file 7: Table S3. A comparison of whole cell current density and reversal potentials between TASK3 clinical variants and matched WT controls.

Additional file 8: Table S4. A comparison of inhibition by extracellular acidification (pH 6.4) between TASK3 clinical variants and WT controls.

Additional file 9: Table S5. A comparison of GPCRs regulation between TASK3 clinical variants and WT controls.

Acknowledgements

We thank the families for their willingness to participate in this study. Some of the authors of this publication are member of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516].

Authors' contributions

MAC, ELV, MTZ, AM, and EWK conceived, coordinated, and supervised the study. MAC compiled the clinical and genetic data. NRD, ST, MTZ, and RU performed computational biology analyses. ELV, RGH, and AM performed electrophysiological and in vitro assays. MAC, ELV, and MTZ wrote the manuscript. All other authors contributed clinical and genetic data. All authors read and approved the final manuscript.

Funding

TBH was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—418081722, 433158657. MAC, TMK, FV, and EWK are supported by the Center for Individualized Medicine at Mayo Clinic. RU, NRD, ST, and MTZ were supported by The Linda T. and John A. Mellowes Endowed Innovation and Discovery Fund, the Genomic Sciences and Precision Medicine Center of Medical College of Wisconsin, and the Advancing a Healthier Wisconsin (AHW) Endowment.

No funding body participated in the design of the study, collection, analysis, or interpretation of data, or in writing the manuscript.

Availability of data and materials

All data generated or analyzed during this study we are able to share are included in this published article and its supplementary information files. Raw genetic sequence data are not available as study participants did not consent to sharing their sequence data publicly. Specific questions or requests can be made to the corresponding authors.

Declarations

Ethics approval and consent to participate

This study was approved by the Mayo Clinic Institutional Review Board (IRB# 12-009346) and local Ethics Committees and conformed to the Helsinki Declaration. All families provided written informed consent to participate in this study. Family 9 was recruited to the Genomics England 100,000 Genomes Project, with written informed consent from parents and children. Families F18 and F19 were previously published [8] and also provided written informed consent to participate in this study to provide updated clinical information. Families F18-F22, F25, and F28 were previously published [5–8] and no new data were provided for this study.

Consent for publication

Written informed consent was obtained from all participants to publish the identifiable data and clinical information in this study.

Competing interests

JJ, KMc, MJGS, and RW are employees of GeneDx. AML and GB are current shareholders and employees of Invitae. The remaining authors declare that they have no competing interests.

Author details

¹Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. ²Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. ³Medway School of Pharmacy, University of Kent and University of Greenwich, Central Avenue, Anson Building, Central Avenue, Chatham Maritime, ME4 4, Kent, TB ME4 4TB, UK. ⁴Bioinformatics Research and Development Laboratory, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. ⁵Department for Women and Child Health, Hospital for Children and Adolescents, University Hospitals, University of Leipzig, Leipzig, Germany. ⁶Children's Hospital of Minnesota, Minneapolis, MN, USA. ⁷Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. ⁸Institute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ⁹Division of Medical Genetics, Northwell Health, Manhasset, NY, USA. ¹⁰Medical Genetics Unit, Department of Medical Sciences, Ferrara University, Ferrara, Italy. ¹¹Division of Neurology, BC Children's Hospital, Vancouver, British Columbia, Canada. ¹²Oxford Centre for Genomic Medicine, ACE Building, Nuffield Orthopaedic centre, Oxford University Hospitals NHS Foundation Trust, Windmill road, Headington, Oxford OX3 7HE, UK. ¹³Département of Genetics, APHP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France. ¹⁴CHU Nantes, Service de génétique médicale, Nantes, France. ¹⁵CHU de Rouen, Service de Néonatalogie, Réanimation pédiatrique, Neuropédiatrie et éducation fonctionnelle de l'enfant, INSERM U 1245, ED497, 76000 Rouen, France. ¹⁶APHP, Hôpital Raymond Poincaré, Hôpitaux Universitaires Paris Ile-de-France Ouest, Pôle pédiatrique, Service de Pédiatrie, Centre de Référence Nord-Est-Ile de France, 92380 Garches, France. ¹⁷APHP, Department of Neuropediatrics, National Reference Center for Neurogenetic Disorders, Hôpital Armand-Trousseau, GHUEP, Paris, France. ¹⁸Service de Néonatalogie, CHU de Caen, Caen, France. ¹⁹Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA. ²⁰Department of Pediatrics, Harbor-UCLA Medical Center, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. ²¹Centre for Rare Diseases, University of Tübingen, Tübingen, Germany. ²²Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. ²³GeneDx, 207 Perry Parkway, Gaithersburg, MD, USA. ²⁴Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. ²⁵Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ²⁶Departments of Pediatrics and Neurology, University of Texas Southwestern Medical Center and Children's Health, Dallas, TX, USA. ²⁷APHP, Département de Génétique et Centre de Référence Déficiences Intellectuelles de Causes Rares, Hôpital de la Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, 75651 Paris, France. ²⁸Pediatrics III, Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany. ²⁹Institute of Human Genetics, University of Leipzig Medical Center, 04103 Leipzig, Germany. ³⁰Service de Génétique Clinique, CHRU de Nancy, F-54000 Vandoeuvre-les-Nancy, France. ³¹Unité INSERM N-GERE UMR_S 1256, Université de Lorraine, Faculté de Médecine, 9 avenue de la Forêt de Haye, CS 50184, Vandoeuvre-les-Nancy, France. ³²Section of Medical Genetics, SUNY Upstate University Hospital,

Syracuse, NY, USA. ³³Molecular Genetics of Neurodevelopmental Disorders, Department of Woman and Child Health, University of Padova, Padua, Italy. ³⁴Pediatric Research Institute, Città della Speranza, Padova, Italy. ³⁵Department of Paediatric Medicine, KK Women's and Children's Hospital, Mount Elizabeth Hospital, Singapore, Singapore. ³⁶Texas Children's Hospital, Houston, TX, USA. ³⁷Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, MN, USA. ³⁸Center for Rare Childhood Disorders, Translational Genomics Research Institute, Phoenix, AZ, USA. ³⁹Department of Genetics, Reims University Hospital, Reims, France. ⁴⁰Joint BCM-CUHK Center of Medical Genetics, Shatin, Hong Kong SAR. ⁴¹Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA. ⁴²Practice of Human Genetics, Bremen, Germany. ⁴³Genetics Center, Orange, CA, USA. ⁴⁴Division of Medical Genetics, CHOC Children's Hospital, Orange, CA, USA. ⁴⁵Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA. ⁴⁶Clinical and Translational Sciences Institute, Medical College of Wisconsin, Human Research Center, Milwaukee, WI, USA. ⁴⁷Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA. ⁴⁸School of Engineering, Arts, Science and Technology, University of Suffolk, Ipswich, UK.

Received: 23 November 2021 Accepted: 19 May 2022

Published online: 13 June 2022

References

- Enyedi P, Czirjak G. Molecular background of leak K⁺ currents: two-pore domain potassium channels. *Physiol Rev*. 2010;90(2):559–605.
- Goldstein SA, Bayliss DA, Kim D, Lesage F, Plant LD, Rajan S. International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. *Pharmacol Rev*. 2005;57(4):527–40.
- Luedi PP, Dietrich FS, Weidman JR, Bosko JM, Jirtle RL, Hartemink AJ. Computational and experimental identification of novel human imprinted genes. *Genome Res*. 2007;17(12):1723–30.
- Cooper A, Butto T, Hammer N, Jagannath S, Fend-Guella DL, Akhtar J, et al. Inhibition of histone deacetylation rescues phenotype in a mouse model of Birk-Barel intellectual disability syndrome. *Nat Commun*. 2020;11(1):480.
- Barel O, Shalev SA, Ofir R, Cohen A, Zlotogora J, Shorer Z, et al. Maternally inherited Birk Barel mental retardation dysmorphism syndrome caused by a mutation in the genomically imprinted potassium channel KCNK9. *Am J Hum Genet*. 2008;83(2):193–9.
- Sediva M, Lassuthova P, Zamecnik J, Sedlackova L, Seeman P, Haberlova J. Novel variant in the KCNK9 gene in a girl with Birk Barel syndrome. *Eur J Med Genet*. 2020;63(1):103619.
- Guo H, Duyzend MH, Coe BP, Baker C, Hoekzema K, Gerds J, et al. Genome sequencing identifies multiple deleterious variants in autism patients with more severe phenotypes. *Genet Med*. 2019;21(7):1611–20.
- Graham JM Jr, Zadeh N, Kelley M, Tan ES, Liew W, Tan V, et al. KCNK9 imprinting syndrome—further delineation of a possible treatable disorder. *Am J Med Genet A*. 2016;170(10):2632–7.
- Mathie A, Veale EL, Cunningham KP, Holden RG, Wright PD. Two-pore domain potassium channels as drug targets: anesthesia and beyond. *Annu Rev Pharmacol Toxicol*. 2021;61:401–20.
- Talley EM, Solorzano G, Lei Q, Kim D, Bayliss DA. Cns distribution of members of the two-pore-domain (KCNK) potassium channel family. *J Neurosci*. 2001;21(19):7491–505.
- Chen X, Talley EM, Patel N, Gomis A, McIntire WE, Dong B, et al. Inhibition of a background potassium channel by Gq protein alpha-subunits. *Proc Natl Acad Sci U S A*. 2006;103(9):3422–7.
- Mathie A. Neuronal two-pore-domain potassium channels and their regulation by G protein-coupled receptors. *J Physiol*. 2007;578(Pt 2):377–85.
- Veale EL, Kennard LE, Sutton GL, MacKenzie G, Sandu C, Mathie A. G(alpha)q-mediated regulation of TASK3 two-pore domain potassium channels: the role of protein kinase C. *Mol Pharmacol*. 2007;71(6):1666–75.
- Veale EL, Hassan M, Walsh Y, Al-Moubarak E, Mathie A. Recovery of current through mutated TASK3 potassium channels underlying Birk Barel syndrome. *Mol Pharmacol*. 2014;85(3):397–407.
- Bando Y, Hirano T, Tagawa Y. Dysfunction of KCNK potassium channels impairs neuronal migration in the developing mouse cerebral cortex. *Cereb Cortex*. 2014;24(4):1017–29.
- Linden AM, Sandu C, Aller MI, Vekovischeva OY, Rosenberg PH, Wisden W, et al. TASK-3 knockout mice exhibit exaggerated nocturnal activity, impairments in cognitive functions, and reduced sensitivity to inhalation anesthetics. *J Pharmacol Exp Ther*. 2007;323(3):924–34.
- Pang DS, Robledo CJ, Carr DR, Gent TC, Vyssotski AL, Caley A, et al. An unexpected role for TASK-3 potassium channels in network oscillations with implications for sleep mechanisms and anesthetic action. *Proc Natl Acad Sci U S A*. 2009;106(41):17546–51.
- Gotter AL, Santarelli VP, Doran SM, Tannenbaum PL, Kraus RL, Rosahl TW, et al. TASK-3 as a potential antidepressant target. *Brain Res*. 2011;1416:69–79.
- Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat*. 2015;36(10):928–30.
- Klee EW, Cousin MA, Pinto EVF, Morales-Rosado JA, Macke EL, Jenkinson WG, et al. Impact of integrated translational research on clinical exome sequencing. *Genet Med*. 2021;23(3):498–507.
- Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D, et al. Identifying facial phenotypes of genetic disorders using deep learning. *Nat Med*. 2019;25(1):60–4.
- McWilliam H, Li W, Uludag M, Squizzato S, Park YM, Buso N, et al. Analysis tool web services from the EMBL-EBI. *Nucleic Acids Res*. 2013;41(Web Server issue):W597–600.
- Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol*. 2011;7:539.
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. *Nucleic Acids Res*. 2000;28(1):235–42.
- Zhang Y. I-TASSER server for protein 3D structure prediction. *BMC Bioinformatics*. 2008;9:40.
- Miller AN, Long SB. Crystal structure of the human two-pore domain potassium channel K2P1. *Science*. 2012;335(6067):432–6.
- Brohawn SG, del Marmol J, MacKinnon R. Crystal structure of the human K2P TRAAK, a lipid- and mechano-sensitive K⁺ ion channel. *Science*. 2012;335(6067):436–41.
- Laskowski RA, Rullmann JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. *J Biomol NMR*. 1996;8(4):477–86.
- Benkert P, Kunzli M, Schwede T. QMEAN server for protein model quality estimation. *Nucleic Acids Res*. 2009;37(Web Server issue):W510–4.
- Studer G, Biasini M, Schwede T. Assessing the local structural quality of transmembrane protein models using statistical potentials (QMEAN-Brane). *Bioinformatics*. 2014;30(17):i505–11.
- Willard L, Ranjan A, Zhang H, Monzavi H, Boyko RF, Sykes BD, et al. VADAR: a web server for quantitative evaluation of protein structure quality. *Nucleic Acids Res*. 2003;31(13):3316–9.
- Holm L, Park J. DALI Lite workbench for protein structure comparison. *Bioinformatics*. 2000;16(6):566–7.
- Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. *Proc Natl Acad Sci U S A*. 2001;98(18):10037–41.
- Rodstrom KEJ, Kiper AK, Zhang W, Rinne S, Pike ACW, Goldstein M, et al. A lower X-gate in TASK channels traps inhibitors within the vestibule. *Nature*. 2020;582(7812):443–7.
- Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. *J Mol Graph*. 1996;14(1):33–8 27–8.
- Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. *J Comput Chem*. 2008;29(11):1859–65.
- Jo S, Lim JB, Klauda JB, Im W. CHARMM-GUI Membrane Builder for mixed bilayers and its application to yeast membranes. *Biophys J*. 2009;97(11):50–8.

38. Cong Q, Grishin NV. MESSA: MEta-Server for protein Sequence Analysis. *BMC Biol.* 2012;10:82.
39. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. *Nucleic Acids Res.* 2005;33(Web Server issue):W382–8.
40. Van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, Rousseau F. A graphical interface for the FoldX forcefield. *Bioinformatics.* 2011;27(12):1711–2.
41. Parra RG, Schafer NP, Radusky LG, Tsai MY, Guzovsky AB, Wolynes PG, et al. Protein Frustratometer 2: a tool to localize energetic frustration in protein molecules, now with electrostatics. *Nucleic Acids Res.* 2016;44(W1):W356–60.
42. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. *J Comput Chem.* 2005;26(16):1781–802.
43. Cornell WDCP, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, et al. A Second generation force field for the simulation of proteins, nucleic acids, and organic molecules. *J Am Chem Soc.* 1995;117:5179–97.
44. Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, et al. Improvements to the APBS biomolecular solvation software suite. *Protein Sci.* 2018;27(1):112–28.
45. Grant BJ, Rodrigues AP, ElSawy KM, McCammon JA, Cavas LS. Bio3d: an R package for the comparative analysis of protein structures. *Bioinformatics.* 2006;22(21):2695–6.
46. The PyMOL Molecular Graphics System. Version 1.8.6.1. Schrödinger, LLC. <https://pymol.org/2/support.html#citing>.
47. Cunningham KP, Holden RG, Escribano-Subias PM, Cogolludo A, Veale EL, Mathie A. Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension. *J Physiol.* 2019;597(4):1087–101.
48. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405–24.
49. ClinGen Sequence Variant Interpretation Recommendation for PM2 -Version 1.0. Working Group Page: <https://clinicalgenome.org/working-groups/sequence-variant-interpretation/>, Date Approved: September 4, 2020., (2020).
50. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 2019;47(D1):D886–D94.
51. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods.* 2014;11(4):361–2.
52. Sundaram L, Gao H, Padigepati SR, McRae JF, Li Y, Kosmicki JA, et al. Predicting the clinical impact of human mutation with deep neural networks. *Nat Genet.* 2018;50(8):1161–70.
53. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. *Genome Res.* 2001;11(5):863–74.
54. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nat Methods.* 2010;7(4):248–9.
55. Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. *Genome Med.* 2020;12(1):103.
56. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature.* 2020;581(7809):434–43.
57. Betancur C, Buxbaum JD. Gene constraint and genotype-phenotype correlations in neurodevelopmental disorders. *Curr Opin Genet Dev.* 2020;65:69–75.
58. Havrilla JM, Pedersen BS, Layer RM, Quinlan AR. A map of constrained coding regions in the human genome. *Nat Genet.* 2019;51(1):88–95.
59. Tripathi S, Dsouza NR, Urrutia R, Zimmermann MT. Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations. *Bioinformatics.* 2020.
60. Kim Y, Bang H, Kim D. TASK-3, a new member of the tandem pore K(+) channel family. *J Biol Chem.* 2000;275(13):9340–7.
61. Rajan S, Wischmeyer E, Xin Liu G, Preisig-Muller R, Daut J, Karschin A, et al. TASK-3, a novel tandem pore domain acid-sensitive K⁺ channel. An extracellular histidine as pH sensor. *J Biol Chem.* 2000;275(22):16650–7.
62. Ashmole I, Vavoulis DV, Stansfeld PJ, Mehta PR, Feng JF, Sutcliffe MJ, et al. The response of the tandem pore potassium channel TASK-3 (K(2P)9.1) to voltage: gating at the cytoplasmic mouth. *J Physiol.* 2009;587(Pt 20):4769–83.
63. Ramanathan A, Savol AJ, Langmead CJ, Agarwal PK, Chennubhotla CS. Discovering conformational sub-states relevant to protein function. *PLoS One.* 2011;6(1):e15827.
64. Shehu A, Kavrakli LE, Clementi C. On the characterization of protein native state ensembles. *Biophys J.* 2007;92(5):1503–11.
65. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, et al. The structure of the potassium channel: molecular basis of K⁺ conduction and selectivity. *Science.* 1998;280(5360):69–77.
66. Niday Z, Tzingounis AV. Potassium channel gain of function in epilepsy: an unresolved paradox. *Neuroscientist.* 2018;24(4):368–80.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

